GLP-1 Drugs and Eating Disorders: A Hidden Crisis Doctors Are Sounding the Alarm On

GLP-1 drugs and eating disorders are turning into a dangerous combination that medical professionals say is being overlooked. While medications like Ozempic, Wegovy, and Zepbound have transformed the weight-loss industry by sharply suppressing appetite, they are also creating serious risks for a vulnerable group of people, those battling anorexia, bulimia, binge eating disorder, or any history of disordered eating.

Doctors, therapists, and treatment centers across the country are reporting a steady rise in patients who have either relapsed or developed an eating disorder for the first time while using these drugs. The easy availability online, aggressive advertising, and lack of clear warning labels are making the problem worse.

When Weight Loss Becomes a Trigger

Take the story of Stevee Williams, a 27-year-old restaurant manager in Houston. Diagnosed with anorexia as a teenager, she had spent years quietly struggling with food and body image. As her sister’s wedding approached, anxiety about how she would look in her bridesmaid dress began to consume her.

Instead of reaching out for support, she went online, lied about her weight and physical condition on a telehealth site, and ordered a bottle of Wegovy pills for $149. She was just five feet tall and already a healthy weight, but she wanted to be smaller.

Williams isn’t alone. Across the country, doctors are seeing patients walk through the doors of treatment centers having ordered powerful GLP-1 medications from websites that barely ask questions.

How Easy Access Is Fueling the Problem

Stories like Williams’ are becoming disturbingly common. Major telehealth platforms officially require users to be at least 18 years old, but providers say younger teens are getting around the rules. Some lie about their age and weight, while others use their parents’ credit cards. In some cases, teens are even getting prescriptions through pediatricians under the umbrella of obesity treatment.

Rebecka Peebles, who handles clinical intake for the national eating disorder treatment provider Monte Nido, said her team sees this every day. According to her, at least three patients show up daily who are on a GLP-1 drug, not for diabetes, but purely for weight loss.

The Research Is Just Beginning to Catch Up

A perspective article published in the New England Journal of Medicine in April pointed out that studies on this issue are still limited. Researchers estimated that more than 420,000 people could end up developing an eating disorder through long-term use of GLP-1 drugs. That’s just over one percent of the 33 million Americans currently using them.

Yet the FDA-approved labels on these medications still don’t list eating disorders as a possible side effect. The agency, when asked, only said it monitors safety signals after drugs hit the market.

Extreme Eating Patterns Documented in Studies

A 2025 study published in Obesity Reviews offered a glimpse into how dangerously low some patients are pushing their food intake while on these drugs. Some examples documented in the study include:

• One patient eating only 400 calories per day
• Another restricting to between 300 and 350 calories daily
• A third surviving on 400 to 600 calories
• One woman drinking only water and Diet Coke for 13 days, losing 21 pounds

That same patient told researchers her long-term plan was to fast for six days each week and eat just once on the seventh. The absence of hunger felt so liberating, she didn’t want it to end.

Why These Drugs Conflict With Eating Disorder Treatment

For many years, recovery from an eating disorder has involved relearning how to recognize natural hunger and fullness cues. GLP-1s essentially silence those signals, undoing one of the foundations of treatment.

Wendy Oliver Pyatt, co-founder of Within Health and Galen Hope in Florida, put it bluntly. According to her, these medications mimic the very behaviors that anorexia produces in the body. The drug becomes another way to suppress hunger, which is exactly what someone in recovery is trying to overcome.

Even teens are being pulled into the mix in unexpected ways. Rebecca Boswell of the Princeton Center for Eating Disorders recalled speaking with a group of eighth-graders about body image, only to have the room break into the Ozempic jingle in unison. She described the moment as deeply unsettling.

Manufacturers and Regulators Pass the Buck

When asked whether their drugs are being misused, manufacturers responded carefully. Novo Nordisk, the maker of Ozempic and Wegovy, said it trusts healthcare professionals to evaluate patient history and risk factors before prescribing. Eli Lilly, which makes Zepbound, also said treatment decisions should be made between doctors and patients, while adding that it continues reviewing safety data including issues related to eating disorders.

Meanwhile, the American Academy of Family Physicians said it has not adopted any recommendations for screening patients for eating disorders before prescribing GLP-1s. The organization argues that it does not see a need to make broad guidelines based on a single clinical concern.

“Anorexic Heroin”: One Man’s Devastating Experience

AJ Jasper, a 40-year-old social worker from Chicago, has lived with anorexia for nearly three decades. Three years ago, while at a healthy weight, he relapsed after buying GLP-1 drugs through various apps without ever seeing a doctor in person. By stacking multiple drugs, he lost 50 pounds in just three to four months.

He calls the apps “frighteningly easy” to use and described the medications as feeling like “anorexic heroin” to his brain. The result was catastrophic. This past winter, Jasper went into triple organ failure affecting his kidneys, liver, and heart. He needed a feeding tube and was too weak to even turn in bed at times.

He has since returned to a healthy weight through outpatient treatment. His warning is clear. Anyone with an eating disorder, he says, should stay far away from these medications.

A Crisis Hiding Inside a Trend

Shirley D., a 62-year-old Navy veteran in Nevada who has lived with binge eating disorder, also turned to Zepbound. While the drug improved her diabetes numbers, it pulled her back into severe food restriction. Her current daily intake of Greek yogurt, half a bagel, and a few nuts has her doctors worried about long-term effects on her bones and joints.

She has lost about 30 pounds, but she is socially withdrawn and avoids dining with friends. As she put it, two voices are battling inside her, and the GLP-1 is winning.

The Bottom Line

GLP-1 drugs and eating disorders are colliding in ways that are still poorly understood. Heavy advertising, easy online access, and a lack of clear warnings are creating real risks for millions of Americans. Until manufacturers, regulators, and healthcare providers take stronger action, awareness from patients and families may be the strongest line of defense.